Discover
SVRA
Savara Inc.
4.92
2 x 3.55
2 x 6.27
bid
ask
+
0.09
1.86%
2 @ 04:55 PM
5.00 +0.08 (1.63%)
| Ytd | -18.41% | |
| 1y | 43.86% |
4.81
day range
4.97
3.37
52 week range
6.94
| Open | 4.82 | Prev Close | 4.83 | Low | 4.81 | High | 4.97 | Mkt Cap | 1.01B |
| Vol | 1.53M | Avg Vol | 1.83M | EPS | -0.58 | P/E | N/A | Forward P/E | -13.41 |
| Beta | 0.20 | Short Ratio | 29.34 | Inst. Own | 106.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 5.33 | 200-d Avg | 5.50 | 1yr Est | 11.06 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | -0.16 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -0.14 | -0.16 | -0.02 | -13.27% |
| 2026-05-12 | 2026-03 | -0.14 | -0.15 | -0.01 | -7.14% |
| 2026-03-13 | 2025-12 | -0.12 | -0.13 | -0.01 | -8.33% |
| 2025-11-12 | 2025-09 | -0.13 | -0.14 | -0.01 | -7.69% |
| 2025-08-13 | 2025-06 | -0.12 | -0.14 | -0.02 | -16.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-10-07 | JP Morgan | Upgrade | Overweight | |
| 2025-12-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2025-12-18 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2025-11-14 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2025-11-13 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2025-10-23 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
Profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-12-08 | ELAM NEVAN C | Director | 106.89K | Stock Award(Grant) |
| 2024-12-11 | ERICKSON ANNE | Officer | 434.67K | Stock Award(Grant) |
| 2025-12-08 | HAWKINS RICHARD JAMES | Director | 161.33K | Stock Award(Grant) |
| 2026-06-21 | LOWRANCE DAVID L. CPA | Chief Financial Officer | 536.03K | Conversion of Exercise of derivative security |
| 2026-07-14 | LUTZ ROBERT MATTHEW | Chief Operating Officer | 328.98K | Stock Award(Grant) |
| 2026-02-12 | MCCRACKEN JOSEPH S | Director | 302.64K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | NEA Management Company, LLC | 24.47M | 120.40M | 11.91% |
| 2026-06-29 | Bain Capital Life Sciences Investors, LLC | 17.60M | 86.60M | 8.57% |
| 2026-06-29 | Venrock Adviser, LLC | 14.75M | 72.55M | 7.18% |
| 2026-06-29 | Deerfield Management Company, L.P | 13.57M | 66.76M | 6.60% |
| 2026-06-29 | Blackrock Inc. | 12.49M | 61.47M | 6.08% |
| 2026-06-29 | TCG Crossover Management, LLC | 12.36M | 60.82M | 6.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 6.16M | 30.33M | 3.00% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 3.94M | 19.40M | 1.92% |
| 2026-08-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.37M | 16.60M | 1.64% |
| 2026-07-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.67M | 8.23M | 0.81% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.56M | 7.66M | 0.76% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 Growth ETF | 1.45M | 7.12M | 0.70% |
Split
| Split | Date |
|---|---|
| 0 : 1 | 2017-04-28 |
| 0.04 : 1 | 2010-04-26 |